The hepatitis B surface antibody test (HBsAb) detects antibodies in the blood to determine if someone is immune to the hepatitis B virus (HBV). A negative or nonreactive result means the individual is not immune.

It detects how much virus is in the blood as a result of very active viral replication.

0.005 to 150 IU/mL

The Hepatitis B Virus E Antigen (HBeAg) test is used to detect the presence of HBeAg in the blood of individuals infected with Hepatitis B virus (HBV). Here's how to interpret the test results: Positive Result: A positive HBeAg result indicates the presence of HBeAg in the blood. Interpretation: HBeAg positivity is typically associated with high levels of HBV replication and indicates active viral replication. It is often observed during the immune-tolerant phase of chronic HBV infection, especially in individuals who acquired the infection perinatally or during early childhood. In acute HBV infection, HBeAg positivity usually precedes the appearance of antibodies to HBeAg (anti-HBe). In chronic HBV infection, HBeAg positivity may indicate increased infectivity and a higher risk of transmitting the virus to others. HBeAg positivity may also be associated with a higher risk of disease progression to liver cirrhosis and hepatocellular carcinoma (HCC), especially in individuals with high levels of HBV DNA and persistently elevated liver enzymes. Negative Result: A negative HBeAg result indicates the absence of detectable HBeAg in the blood. Interpretation: HBeAg negativity may occur during the immune clearance phase of chronic HBV infection, characterized by fluctuating levels of HBV DNA and liver enzymes. It may also occur in individuals with inactive or low-replicative chronic HBV infection, often associated with the development of anti-HBe antibodies. In acute HBV infection, HBeAg negativity may occur during the convalescent phase, following the seroconversion from HBeAg positivity to anti-HBe positivity. HBeAg negativity may also occur in individuals undergoing antiviral therapy for chronic HBV infection, as a response to treatment leading to viral suppression. Clinical Correlation: Interpretation of HBeAg test results should be done in conjunction with other markers of HBV infection, including HBsAg, anti-HBe, HBV DNA levels, and liver function tests. Additional tests, such as liver imaging studies and liver biopsy, may be necessary to assess the extent of liver damage and guide treatment decisions. Treatment Implications: HBeAg status plays a crucial role in determining the need for antiviral therapy and the choice of treatment regimens in individuals with chronic HBV infection. HBeAg-positive individuals with high levels of HBV DNA and elevated liver enzymes may benefit from antiviral therapy to suppress viral replication and prevent disease progression. HBeAg-negative individuals with evidence of active liver disease, such as elevated liver enzymes and significant liver fibrosis, may also be candidates for antiviral therapy. Monitoring: Regular monitoring of HBeAg status, HBV DNA levels, and liver function tests is essential to assess treatment response and disease progression in individuals with chronic HBV infection. Interpretation of HBeAg test results should be performed by healthcare providers experienced in the diagnosis and management of HBV infection. It's essential to consider the patient's clinical history, disease stage, and other relevant factors when interpreting these results and determining the appropriate treatment and management plan.

Blood